Liposomal daunorubicin in tumor stage cutaneous T-cell lymphoma
✍ Scribed by U. Wollina; K. Hohaus; J. Schönlebe; E. Haroske; E. Köstler
- Book ID
- 106123227
- Publisher
- Springer-Verlag
- Year
- 2003
- Tongue
- English
- Weight
- 304 KB
- Volume
- 129
- Category
- Article
- ISSN
- 1432-1335
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND In single center studies and case reports, it was shown that pegylated liposomal doxorubicin (PEG‐DOXO) was effective as second‐line therapy for patients with cutaneous T‐cell lymphoma (CTCL). The objective of this study was to evaluate the efficacy and toxicity of single
Four patients with late stage cutaneous T cell lymphoma (IB-IVA) who had failed at least two previous therapies were treated with DAB 389 IL2 at 9 or 18 µg/kg as 15-min intravenous infusions daily for 5 days every 3 weeks for eight cycles. Mild vascular leak syndrome (VLS) with transient edema, hypo
## Abstract Cutaneous T‐cell lymphoma (CTCL) is a heterogeneous group of extra‐nodal non‐Hodgkin lymphomas with primary manifestation in the skin with poor treatment options in the advanced stages. As basis for future immune‐therapeutic strategies we have investigated the possible expression of tum